Effect of different doses of Atorvastatin in contrast-induced nephropathy

Chinese Journal of Interventional Imaging and Therapy

Volumn 7, Issue 5, 2010, Pages 520-524

  Yu, Deng Ji ^a   Su, Jin Zi ^a   Chen, Guang Ling ^a   Cai, Wen Qin ^a   Jin, Xue Qing ^a   Chai, Da Jun ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

Atorvastatin; Contrast induced nephropathy; High sensitivity C reactive protein

Indexed keywords

ALBUMIN; ALPHA 1 MICROGLOBULIN; ATORVASTATIN; C REACTIVE PROTEIN; CONTRAST MEDIUM; CREATININE; CYSTATIN C; NITROGEN; TRANSFERRIN; UREA;

ACUTE CORONARY SYNDROME; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; TRANSFERRIN BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; VASCULAR ENDOTHELIUM;

EID: 84860539884     PISSN: 16728475     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. 2005, 2(6): 437-441.
2. 2006, 22(11): 1759-1761.
3. 2009, 37(5): 389-393.
4. Mehran R, Aymong E D, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. J Am Coll Cardiol, 2004, 44(7): 1393-1399.
5. Xinwei J, Xianghua F, Jing Z, et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol, 2009, 104(4): 519-524.
6. Patti G, Pasceri V, Colonna G, et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol, 2007, 49(27): 1272-1278.
7. Sakkinen P, Abbott R D, Curb J D, et al. C-reactive protein and myocardial infarction. J Clin Epidemiol, 2002, 55(5): 445-451.
8. 2007, 2(8): 457-459.
9. 2005, 13(12): 767-770.
10. Tumlin J, Stacul F. Pathophysiology of contrast-induced nephropathy. Am J Cardiol, 2006, 98(6A): 14K-20K.
11. Efstratiadis G, Pateinakis P, Tambakoudis G, et al. Contrast media-induced nephropathy: case report and review of the literature focusing on pathogenesis. Hippokratia, 2008, 12(2): 87-93.
12. Mason J C, Ahmed Z, Mankoff R, et al. Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res, 2002, 91(8): 696-703.
13. Patti G, Nusca A, Chello M, et al. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention. Am J Cardiol, 2008, 101(3): 279-285.
14. Lecian D, Demova H, Lodererova A, et al. Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res, 2006, 29(3): 135-143.